Nuvo Research Inc. (TSX: NRI), a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, today announced its financial and operational results for the quarter ended March 31, 2009.
<<
Recent Corporate Developments:
- Successfully completed all Pennsaid(R) studies necessary to resubmit
the application for Pennsaid approval to the United States Food and
Drug Administration (FDA). The FDA confirmed that it has accepted
this filing as a complete response to its Approvable Letter for
Pennsaid dated December 28, 2006 and pursuant to the Prescription
Drug User Fee Act provided the Company with a date of August 5, 2009
(the PDUFA Date) by which the FDA intends to advise Nuvo on
Pennsaid's approvability
- Received net proceeds of $3.7 million from the exercise of warrants
under the warrant incentive program
- Was awarded the bronze medal in the Science and Medical category of
the 2009 Edison Awards for the Company's High Throughput
Experimentation platform
- Was advised that PAIN(R) , the world's leading publication on pain
research and treatments and the official journal of the International
Association for the Study of Pain will be publishing an article
outlining the successful results of the Company's 112 efficacy trial
in its June 2009 issue
>>
"With our PDUFA Date rapidly approaching, we remain highly optimistic about Pennsaid's potential for approval and are continuing discussions with potential United States licensing partners," said Henrich Guntermann, President and Chief Executive Officer of Nuvo Research.
